Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Jupiter Neurosciences has entered into a term sheet to acquire exclusive, perpetual U.S. licensing rights to ALA-002, a patented next-generation non-racemic MDMA therapeutic developed by PharmAla Biotech. The acquisition positions Jupiter at the forefront of MDMA-based psychedelic medicine, coinciding with President Trump's Executive Order accelera…